Real-world evidence from over 30,000 users confirms a low incidence of adverse reactions1.
No universal contraindications.
Other chronic conditions: No known interactions with medications; used by individuals with diabetes, heart disease, hypertension, asthma, co-occurring mental health conditions, neurodivergence, and brain injuries/ disorders without reported safety concerns.
Pregnancy: Not licensed for use; no safety concerns identified in existing studies, research ongoing.
Breastfeeding: Safe to use; no effect on breast milk production.
Postpartum: Appears safe for postpartum depression and successfully used in NHS pilots.
Children and Adolescents: Not licensed for use; studies ongoing for ages 14+
Evidence breakdown shown is based on real-world data collected from 28,000 users until June 2024. Please note percentages may vary slightly with time because of the constantly growing number of patients.
Adverse events should be reported. Report forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Flow Neuroscience by emailing support@flowneuroscience.com.
As neuromodulation continues to gain traction, we understand the need for hands-on experience. That’s why we offer complimentary training, continuous clinical support, and access to a demo device, so you can explore the benefits of Flow firsthand. Our mission is to expand access to proven mental health treatments, enabling clinicians to provide cutting-edge care that improves patient choice and outcomes.
See how Flow can become part of your treatment offerings—request a demo and start transforming patient care today.
Data on file. Flow Neuroscience Real-world reports.